Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 2/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.45 |
| ▸ | HTR2A | P28223 | 3/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 3/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4723215 | 0.84 | CNR2 (0.49) | KDM4EL3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL2073609 | 0.81 | TAAR1 (0.57) | TAAR1RAB9AAOC3MEN1KMT2A | |
| SCHEMBL9853050 | 0.79 | SLC6A4 (0.54) | — | |
| SCHEMBL8196236 | 0.78 | HRH1 (0.55) | HTR2AHRH1LMNAMTNR1AMTNR1B | |
| SCHEMBL15904064 | 0.78 | CYP2C19 (0.49) | RAB9ALMNABCAT2 | |
| SCHEMBL8008005 | 0.77 | GRIN1 (0.45) | GRIN1GRIN2AHTR2ATAAR1KDM4E | |
| SCHEMBL9852959 | 0.77 | MTNR1A (0.57) | MTNR1AMTNR1BCYP3A4 | |
| SCHEMBL27396353 | 0.75 | EPHX1 (0.54) | RAB9AAOC3LMNABCAT2MEN1 | |
| SCHEMBL27468983 | 0.73 | BCAT2 (0.46) | KDM4ELMNABCAT2MEN1KMT2A | |
| SCHEMBL27418259 | 0.73 | LMNA (0.44) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4438136-A | INHIBITION OF THROMBOXANE ACTIVITY | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1984-03-20 | — | — | US | claimed |
| EP-0013608-B1 | SUBSTITUTED BICYCLO (2,2,1)HEPTANES AND HEPT-2-ENES AND THEIR PHARMACEUTICAL COMPOSITIONS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1983-06-15 | — | — | EP | claimed |
| US-20060004062-A1 | Compounds for inhibiting insulin secretion and methods related thereto | MITOKOR (US) | 2006-01-05 | — | — | US | disclosed |
| US-6958352-B2 | Compounds for inhibiting insulin secretion and methods related thereto | SMITHKLINE BEECHAM CORPORATION (US) | 2005-10-25 | — | — | US | disclosed |
| EP-1472214-A2 | COMPOUNDS FOR INHIBITING INSULIN SECRETION AND METHODS RELATED THERETO | SmithKline Beecham Corporation (US) | 2004-11-03 | — | — | EP | disclosed |
| CN-1494592-A | Nucleic acid expressed in hypothalamus or muscle tissue in obese animals | ���и��о��ɷ�����˾ | 2004-05-05 | — | — | CN | disclosed |
| US-20040044049-A1 | Compounds for inhibiting insulin secretion and methods related thereto | MITOKOR | 2004-03-04 | — | — | US | disclosed |
| WO-2003066035-A2 | COMPOUNDS FOR INHIBITING INSULIN SECRETION AND METHODS RELATED THERETO | SMITHKLINE BEECHAM CORPORATION (US) | 2003-08-14 | — | — | WO | disclosed |
| EP-0441226-A1 | (cyanomethyl)pyridines useful as PAF antagonists | J. URIACH & CIA. S.A. (ES) | 1991-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004062-A1 | Compounds for inhibiting insulin secretion and methods related thereto | IAPP, GPR119, INSR | GRIN1 815/4885GRIN2A 2095/4885HTR2A 1236/4885 |
| US-20040044049-A1 | Compounds for inhibiting insulin secretion and methods related thereto | IAPP, GPR119, IRS1 | GRIN1 566/4885GRIN2A 1845/4885HTR2A 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.